Asthma and the COPD segment will be significantly driven by the sudden increase in the patient population, according to Allied Market Research.
Asthma is interpreted as a respiratory disorder that affects the airway system of a human body. This chronic disease often turns fatal if left untreated. There are chances that the patient’s conditions can even worsen, resulting in extreme respiratory problems. Although there are several drugs available in the market to treat asthma, the present day drug manufacturers boast of treat the condition effectively and successfully.
The appalling results of asthma drug trials have now become a talking point of all medical conference. These trials are under intense scrutiny than ever. GlaxoSmithKline has provided clarity on its intensions to fill in the growing vacuum in sales. In December 2015, the company received an approval to market the Nucala. The drug works as an add-on treatment for adults combating severe refractory eosinophilic conditions.
The prevention as well as long -term control are effective ways of stopping asthma even before the condition occurs. Long-term control drugs effective in asthma are Theophylline, Leukotriene modifiers, Long-acting beta agonists, Inhaled corticosteroids and Combination inhalers amongst others. On the other hand, the quick relief medications for asthma include Oral and intravenous corticosteroids, Short-acting beta agonists and Ipratropium (Atrovent). Moreover, there is strong demand for allergy medications. These drugs play an important role when the disease is triggered or the condition worsens due to allergies. Such drugs include allergy shots (immunotherapy) and Omalizumab (Xolair).
Asthma drug manufacturers have been seen investing generously on R&D. Last year a U.K.-based biopharmaceutical brand, Atopix Therapeutics, raised funds to advance its key product OC459, effective in treating asthma.